FBR & Co reaffirmed their outperform rating on shares of Omeros Corporation (NASDAQ:OMER) in a research report released on Tuesday. FBR & Co currently has a $38.00 price target on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. S&P Equity Research boosted their price objective on Omeros Corporation from $7.65 to $8.63 in a report on Monday. Cantor Fitzgerald reissued a buy rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group lowered their price objective on Omeros Corporation from $30.00 to $19.00 and set a buy rating for the company in a report on Wednesday, August 10th. WBB Securities reissued a buy rating and issued a $75.00 price objective on shares of Omeros Corporation in a report on Monday. Finally, Wedbush reissued an outperform rating and issued a $56.00 price objective (down from $62.00) on shares of Omeros Corporation in a report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $32.45.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) opened at 7.50 on Tuesday. Omeros Corporation has a 52-week low of $7.20 and a 52-week high of $16.80. The firm’s market capitalization is $294.70 million. The firm’s 50-day moving average price is $10.41 and its 200-day moving average price is $11.57.

Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.18. The business had revenue of $10 million for the quarter, compared to analysts’ expectations of $9.80 million. During the same period in the previous year, the firm posted ($0.44) earnings per share. The firm’s revenue was up 212.5% compared to the same quarter last year. On average, equities analysts predict that Omeros Corporation will post ($1.55) earnings per share for the current fiscal year.

In other news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the transaction, the vice president now directly owns 179,597 shares in the company, valued at $1,959,403.27. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total value of $183,804.00. Following the transaction, the vice president now owns 179,497 shares of the company’s stock, valued at $2,074,985.32. The disclosure for this sale can be found here. Insiders own 13.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Eidelman Virant Capital acquired a new position in shares of Omeros Corporation during the third quarter valued at about $1,763,000. Gradient Investments LLC increased its position in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares in the last quarter. Stifel Financial Corp increased its position in shares of Omeros Corporation by 4.2% in the second quarter. Stifel Financial Corp now owns 375,773 shares of the biopharmaceutical company’s stock valued at $3,953,000 after buying an additional 15,036 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Omeros Corporation by 30.4% in the second quarter. Mackenzie Financial Corp now owns 114,400 shares of the biopharmaceutical company’s stock valued at $1,203,000 after buying an additional 26,700 shares in the last quarter. Finally, State Street Corp increased its position in shares of Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock valued at $9,274,000 after buying an additional 126,595 shares in the last quarter. Institutional investors and hedge funds own 48.04% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.